Pheochromocytoma – Medxy AI

Safety of Biopsy in Pheochromocytoma and Paraganglioma: What a Global Study Found

By MedXY 05/15/2026

This international study found that biopsy of pheochromocytoma and paraganglioma had low mortality and low serious complication rates, suggesting biopsy may be reasonable in carefully selected patients with expert management.

Diabetes & Endocrinology news Oncology

Most Bilateral Adrenal Lesions Are Benign and Concordant, but Asynchronous Presentation Signals Higher Malignancy Risk

By MedXY 05/13/2026

A large retrospective cohort shows that bilateral adrenal masses are usually benign and concordant, but asynchronous or discordant lesions identify a clinically important subgroup enriched for malignancy and pheochromocytoma.

Anesthesiology Diabetes & Endocrinology news

Preemptive Magnesium Sulfate Infusion Significantly Stabilizes Hemodynamics During Pheochromocytoma Resection

By MedXY 01/19/2026

A randomized, double-blind trial confirms that preemptive magnesium sulfate reduces intraoperative hemodynamic instability by nearly 50% in patients undergoing pheochromocytoma and paraganglioma resection, providing a safe and effective adjunct to standard anesthetic protocols.

Diabetes & Endocrinology Oncology

Targeting Tumor Hypoxia Pathways: Belzutifan’s Promise in Advanced Paraganglioma and Pheochromocytoma Treatment

By MedXY 10/25/2025

This article reviews a phase 2 trial of belzutifan, a HIF-2α inhibitor, demonstrating durable antitumor activity and manageable safety in advanced pheochromocytoma and paraganglioma, highlighting its potential as a targeted therapy.